Beta Bionics (NASDAQ:BBNX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.

A number of other equities analysts have also recently commented on BBNX. Stifel Nicolaus dropped their price target on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Bank of America lowered shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Robert W. Baird dropped their target price on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Finally, Truist Financial cut their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Beta Bionics Stock Performance

NASDAQ:BBNX opened at $10.02 on Friday. The stock’s fifty day moving average is $12.71 and its 200 day moving average is $21.15. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The firm has a market capitalization of $444.69 million, a PE ratio of -5.14 and a beta of 5.60.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The company had revenue of $32.12 million during the quarter.

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. The trade was a 31.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Mike Mensinger sold 2,200 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the sale, the insider directly owned 80,752 shares of the company’s stock, valued at approximately $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 34,705 shares of company stock valued at $945,653 over the last quarter.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after purchasing an additional 1,818 shares during the period. Invesco Ltd. increased its holdings in Beta Bionics by 140.9% during the fourth quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock valued at $3,576,000 after buying an additional 68,640 shares during the period. XTX Topco Ltd bought a new position in Beta Bionics in the fourth quarter worth approximately $1,340,000. Voloridge Investment Management LLC raised its stake in Beta Bionics by 549.6% in the fourth quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock worth $4,621,000 after buying an additional 128,301 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in Beta Bionics by 572.7% during the fourth quarter. Tudor Investment Corp ET AL now owns 259,632 shares of the company’s stock worth $7,911,000 after buying an additional 221,039 shares during the period.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.